Jan 09, 2024 / 06:30PM GMT
Rachel Marie Vatnsdal Olson - JPMorgan Chase & Co, Research Division - Analyst
Perfect. Hi. Good afternoon, everyone. This is Rachel Vatnsdal from the life science tools and diagnostics team here at JPMorgan. I am joined on stage by Revvity and Prahlad, the CEO. So as is typical, this is going to be a 40-minute session. It will be roughly 20 minutes of a presentation followed by 20 minutes of Q&A. For any of you in the audience have questions, feel free to ping me.
With that, I will pass it off to Prahlad.
Prahlad R. Singh - Revvity, Inc. - CEO, President & Director
Good morning, everyone, and thank you, Rachel, for inviting us again to share our exciting story. And I also want to sort of commend you and your colleagues for being able to pull this off flawlessly year-over-year.
Before I begin, I wanted to invite your attention to our safe harbor statement and encourage you to visit the Investors section on our website, revvity.com for any forward-looking statements and additional disclosures that are made here today.
For
Revvity Inc at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot